Systemic allergic symptoms require more urgent attention and include: Cutaneous manifestations : widespread urticaria (raised, itchy welts), generalised pruritus, flushing, or angioedema affecting the face, lips, tongue, or throat Respiratory symptoms : shortness of breath, wheezing, throat tightness, or stridor (high-pitched breathing sound) Gastrointestinal symptoms : nausea, vomiting, abdominal cramping, or diarrhoea (though these can also be common non-allergic side effects of GLP-1 agonists) Cardiovascular symptoms : dizziness, light-headedness, rapid or weak pulse, or feeling faint Anaphylaxis represents the most severe form of allergic reaction and is characterised by the rapid onset of symptoms affecting multiple organ systems
I would very much like to do a version for the young boys
Luckily, Dr
Note: Terms have changed from 2025: With coverage: As low as $25/fill, $100/month max savings (was $150), $1,300/year cap (was $1,950) Without coverage: As low as $499/month , up to $620/month savings, $8,060/year cap (increased from $3,941) Tip: For higher doses without coverage, LillyDirect vials ($449/mo) may now be cheaper than the savings card ($499/mo)
100 percent subcutaneous | | Reported weight data | 12.4 % (36 mg, 72 wk, ATTAIN-1) | 24.2 % (12 mg, 48 wk, Phase 2) | | Food restriction | None | Not applicable | | Status | FDA-approved (Foundayo, April 2026) | Research substance, not approved | The table illustrates that the higher weight values of retatrutide result from a broader receptor activation and the injection-driven complete entry of the active substance, while orforglipron has its strength in ease of administration and oral availability